Market Research Logo

Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H2 2016

Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Review, H2 2016’, provides an overview of the Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy)
    • The report reviews pipeline therapeutics for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) therapeutics and enlists all their major and minor projects
    • The report assesses Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy)
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy)
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) Overview
    Therapeutics Development
    Pipeline Products for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Overview
    Pipeline Products for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Comparative Analysis
    Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Therapeutics under Development by Companies
    Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Therapeutics under Investigation by Universities/Institutes
    Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Unknown Stage Products
    Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Products under Development by Companies
    Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Products under Investigation by Universities/Institutes
    Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Companies Involved in Therapeutics Development
    Alkeus Pharmaceuticals, Inc.
    Biovista Inc.
    GenSight Biologics S.A.
    Ixchel Pharma, LLC
    Khondrion BV
    Spark Therapeutics, Inc.
    Stealth BioTherapeutics Inc.
    Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    BVA-202 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BVA-203 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drug for Lebers Hereditary Optic Neuropathy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    elamipretide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy to Activate ND4 for Leber's Hereditary Optic Neuropathy - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GS-010 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GS-011 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IXC-201 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IXC-203 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KH-176 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SPK-LHON - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Dormant Projects
    Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Product Development Milestones
    Featured News & Press Releases
    Sep 08, 2016: GenSight Biologics Receives Approval to Include Teenage Patients in RESCUE and REVERSE Phase III Trials with GS010 in Leber’s Hereditary Optic Neuropathy
    Jun 08, 2016: GenSight Biologics Announces Additional Promising Results of Its Phase I/II Study with GS010 for the Treatment of Leber’s Hereditary Optic Neuropathy (LHON)
    Jun 01, 2016: Stealth BioTherapeutics Initiates Phase 2 Study of Elamipretide in Leber's Hereditary Optic Neuropathy
    Feb 29, 2016: GenSight Biologics Enrolls First Patient in Pivotal Phase III Program of GS010 in Leber’s Hereditary Optic Neuropathy
    Sep 10, 2015: GenSight Biologics Receives IND Acceptance from FDA to Enter Phase III with GS010
    Dec 15, 2014: New CMO joins Khondrion
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy), H2 2016
    Number of Products under Development for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Comparative Analysis by Unknown Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Alkeus Pharmaceuticals, Inc., H2 2016
    Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Biovista Inc., H2 2016
    Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by GenSight Biologics S.A., H2 2016
    Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Ixchel Pharma, LLC, H2 2016
    Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Khondrion BV, H2 2016
    Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Spark Therapeutics, Inc., H2 2016
    Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Stealth BioTherapeutics Inc., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Dormant Projects, H2 2016
    List of Figures
    Number of Products under Development for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy), H2 2016
    Number of Products under Development for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Targets, H2 2016
    Number of Products by Stage and Targets, H2 2016
    Number of Products by Mechanism of Actions, H2 2016
    Number of Products by Stage and Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report